Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of futibatinib plus pembrolizumab in Japanese patients with solid tumors
jRCT2080224975Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of futibatinib and pembrolizumab in Nonhematologic neoplasms, esophageal cancer and non-small cell lung cancer (NSCLC), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of futibatinib + pembrolizumab and Preliminary antitumor efficacy. Started Dec 2019; status: completed.
02
Drugs
futibatinibpembrolizumab
03
Conditions
Nonhematologic neoplasmsesophageal cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224975.